David Cohen has over 30 years of experience in clinical research and development, most recently as an independent consultant. He was previously the Chief Science Officer of Elutin Inc, which developed local drug delivery platforms. Prior to that, he spent 20 years at Novartis in various roles including leading drug-device combination programs and clinical evaluation teams. He has authored several patents and publications in thrombosis and cardiovascular disease.

1. David S. Cohen Ph.D. Curriculum Vitae 1
Curriculum Vitae
David S. Cohen, Ph.D.
10008 Alegria Drive, Las Vegas, NV 89144
Mobile: (908) 723-7337
Email: sssumnconsulting@gmail.com
Employment History:
David S. Cohen Ph.D., Consulting, Las Vegas, NV 2011 - Present
Site-Specific Solutions for Unmet Medical Needs Consulting, LLC: Proposing site-specific, local
treatment modalities in the areas of cardiovascular and peripheral arterial disease, oncology,
orthopedics, and gynecology. Liasoning with medical device, drug delivery, pharmaceutical, and
biotech companies to provide adjunctive therapeutic options or platforms from which to package
and carry a therapy to the desired physiological site.
Elutin Inc. and Elutin Vascular Inc., Las Vegas, NV 2013 – 2015
Co-Founder, President and Chief Science Officer
Elutin was a Medical Technology company predicated on developing patent-protected, site-specific,
local therapies delivering ‘outside the biological tube’ therapeutic deliverable biodegradable
platforms for the treatment of unmet or inadequately met medical needs in the areas of peripheral
arterial disease, end-stage renal disease, oncology, orthopedics, central nervous system disorders
and erectile dysfunction.

2. David S. Cohen Ph.D. Curriculum Vitae 2
COHENMedical, LLC , Boonton, NJ 2011 -2013
Founder and Chief Science Officer
Development of local, site-specific drug delivery platforms to patients with advanced peripheral
arterial disease and its most severe manifestation, Critical limb Ischemia. The company was sold in
August 2013.
Novartis Pharmaceuticals Corp, East Hanover, NJ
Principal Medical Scientific Expert/ Co-Leader of the Novartis Drug-Eluting Device
Program 2001 - 2011
Identified and determined the feasibility of diverse medical device company platforms for
cardiovascular and non-cardiovascular drug-delivery applications. Identified and recommended
drugs of varying mechanisms of action for local drug delivery therapy platforms such as drug -
eluting stents, vascular access grafts, surgical wraps and meshes, orthopedic and ocular implants,
anti-arrhythmic and intra-ventricular assist devices, anti-embolic CABG platforms, passive cardiac
assist devices, bronchial stents, and otolaryngology applications. To date, nine companies have or
had out-licensing agreements with Novartis from which three platforms have attained regulatory
approval or were or are currently in clinical trials.
Principal Medical Scientific Expert in Cardiovascular/Metabolism Research and
Development 2004 - 2011
Led and/or conducted clinical ‘due diligence’ evaluation teams for the Business, Development and
Licencing and Mergers and Acquisitions groups for in-licensing candidates in vascular,
antithrombotic, antihypertensive, anti-diabetic and anti-obesity indications. These included the anti-
platelet agent Elinogrel, the anticoagulants Rivaroxiban (Xeralto@
), Apixaban (Eliquis@
) and
Dabigatran (Pradexa@
), recombinant Relaxin (Serelaxin@
) for acute decompensated heart failure,
and recombinant Human Elastase to enhance maturation and function of venous-arterial fisulas in
renal hemodialysis. Planning and design member of numerous Clinical Trial Teams, assisting in
protocol development and review, and regulatory planning. Coordinated DSM/DSMBs. Reviewer
of manuscripts for numerous journals such as Thrombosis Research, The Journal of Cardiovascular
Pharmacology, The European Journal of Interventional Cardiology and Cardiovascular
Therapeutics (formerly Cardiovascular Drug Reviews).
Lotrel Clinical Research Manager/Publication Manager 2003 - 2004
ACCOMPLISH (Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving
with Systolic Hypertension) Data Safety Management Board coordinator. Member of the
ACCOMPLISH megatrial trial team and co-clinical trial leader of the Lotrel superiority trial.
Oversaw all Lotrel publication strategies. Composed manuscripts and abstracts of clinical trial
protocols, data, and final reports

3. David S. Cohen Ph.D. Curriculum Vitae 3
Executive Director/International Project Team Leader 2001 - 2003
Led two cholesterol lowering ‘Statin’ projects in the Novartis Cardiovascular/Metabolism Project
Management group: Lescol (Fluvastatin) involving Life Cycle Management, Phase 4 post-
marketing studies; and Pitavastatin in phase 2 and 3 development. Oversaw the Pitavastatin
tetrapartide (Novartis, Nissan Pharma, Sankyo Pharma and Kowa Pharma) decision board.
Distinguished Research Fellow, Cardiovascular/Metabolic Research 2000 -2001
Preclinical Therapeutic Area leader and Representative to Project Management and Translational
Medicine. Responsible for critical evaluations of internal and external opportunities and subsequent
‘shepherding’ from preclinical to Phase 2A clinical studies.
Principal Fellow, Cardiovascular Research 1996 - 2000
Led preclinical, drug discovery research groups (4-10 scientists) in the areas of renal disease,
cardioprotection, hypertension, thrombosis, lipid regulation and modulating strategies, and anti-
diabetic projects (PPAR agonists, GLP-1 analogs, DPP-4 antagonists, etc.).
Ciba Pharmaceuticals Corp., Summit, NJ
Senior Fellow 1992 - 1996
Senior Research Scientist 1988 - 1992
Research Scientist 1984 - 1988
Post-Doctoral Fellow 1982 - 1984
Doctoral Candidate, Univ. MA School of Medicine, Worcester and Boston, MA 1977 - 1982
Research Associate, Special Hematology, Columbia Univ. College of Physicians & Surgeons, NY, NY
1974-1977
Adjunct Lecturer in Biology, City University of New York, NY 1972 -1975
Clinical/Preclinical Research and Development and Project Management
Experience:
• Invited Speaker: University of Medicine and Dentistry of New Jersey (Topic: New
Antithrombotics: Arterial meets Venous, finally east meets west………’what a bloody mess!’)
• Guest lecturer (Topic: Device mediated local drug delivery: future paradigms) at Bruce
Rappaport Medical School, Haifa, Israel and Hebrew University of Jerusalem, Hadassah
Medical School, Israel.
• Novartis Expert to Promus Element DES FDA advisory panel
• Novartis Expert to Xience V DES FDA advisory panel.

4. David S. Cohen Ph.D. Curriculum Vitae 4
• Presented ‘Local Drug Delivery’ opportunities at IM4 Vancouver conference.
• Chaired ‘future antithrombotics’ workshop.
• Presenter at IM3 Medical Device Company Forum on “synergies between ‘Big Pharma’ and site-
specific local drug delivery”.
• Participant in thrombosis expert advisory panel.
• Participant in forum on diabetic cardiovascular disease (clinical manifestations,
mechanistic approaches, future market trends).
• Led six Deal Evaluation teams examining opportunities in dyslipidemia and thrombosis.
• Strategic representative on four additional Deal Evaluation Teams.
• Thrombosis expert on Prexige (COX-2 Inhibitor) International Project Teams.
• Metabolic/Cardiovascular Disease representative to four International Project Teams.
• Research representative to the ‘Proof of Research in Development’ Team (Project Mgmt).
• Member of the Cardio-Renal International Project Team.
• Member of Novartis Due-Diligence/Deal Evaluation Thrombosis/Hypertension in-licensing
program.
• Member of Novartis’ Cardiovascular Disease Task Force on Restenosis and Thrombosis.
• Member of the Ciba International Strategic Alignment Committee on Renal Disease.
• Leading Scientist in Ciba/Novartis research efforts in the study of chronic renal disease.
• Member of the Ciba Thrombosis Strategic Alignment Team.
• Ciba-Geigy Research Coordinator of the Queen’s University (Kingston, Ontario, Canada)
Nitric Oxide Donor synthetic and pharmacology project.
• U.S. Project Team Leader of Nitric Oxide Donor Project.
• Development Project Team Member, Preclinical Research Project leader for CGS 22652
(dual thromboxane antagonist/thromboxane synthase inhibitor) and REVASC (rec-Hirudin).
• Composed preclinical sections (section 6A) of nine IND submissions.
• Project Leader, Dual Thromboxane Antagonist/Thromboxane Synthase Inhibitor Project.
• Aided in the ‘startup’ of a new research group in platelet function/inhibition.
• Conducted research in thrombosis, coagulopathies. hypertension, renal disease, and heart failure
Career Development:
• George Washington University/ESI Program in Project Management
• Novartis Global Project Management Workshop, Princeton, NJ.
• Novartis Global Project Management Workshop, Basel, Switzerland.
• Global Novartis Research Conference, Florence, Italy.
• Immunologically Mediated Atherogenesis Workshop, Vienna, Austria.
• PRIDE (Proof of Research in Development) International Workshop, Basel, Switzerland.
• Principles of Preclinical and Clinical Safety Workshop, Paris, France.
• Product Life-Cycle Management Workshop, Basel, Switzerland.
• Diversity Training Workshop, Morristown, NJ.
• Research Project Team Member Workshop, Murray Hill, NJ.
• Project Team Effectiveness Workshop, Princeton, NJ.
• Project Team Management Workshop, Princeton, NJ.
• Advanced Statistics for the Pharmaceutical Scientist New Brunswick, NJ.

5. David S. Cohen Ph.D. Curriculum Vitae 5
Patent and Invention Disclosures:
D.S. Cohen. Site specific drug delivery wraps, systems and methods of use thereof related
applications. U.S. Patent Application No. 14/181,353 (based on 61/765,842), International
Application No. PCT/US14/16568, Filed 2014
D.S. Cohen. Site specific drug delivery wraps, systems and methods of use thereof. Application
Ser. No. 61/765,842 filed 2013.
D.S. Cohen. A pharmaceutical composition comprising LBM 642 and other PPARα/γ agonists
alone and in combination with other active ingredients as elutants from dug-releasing intravascular
devices to prevent reocclusion. Case 4-32165P1/USN, filed 2004.
D.S. Cohen. A pharmaceutical composition comprising PDE5 inhibitors and other active
ingredients for the treatment of male erectile dysfunction in hypertensive, diabetic, dyslipidemic
and depressed patients. Case 4-32165B/USN, filed 2004.
D.S. Cohen. Devices and methods for delivering MMP inhibitors. Case 4-3289A/USN, filed 2003.
D.S. Cohen. Multiple combinations of multiple antihypertensive agents and aldosterone
modulators. 4-32165A/USN, filed 2002.
D.S. Cohen and A.J. Trapani. Treatment of chronic progressive renal failure with CGS 30440.
Patent Docket - 4-20590/P1/CGC 1830/Prov, filed 1995.
M. deGasparo, R.L. Webb and D.S. Cohen. A pharmaceutical combination composition (benazepril
+ valsartan) for the treatment of hypertension, congestive heart failure and renal failure. Patent
Docket - 4-20402A, filed 1995.
D.S.Cohen. Use of CGS 22652 and analogs thereof, selective dual thromboxane rececptor
antagonists/thromboxane synthase inhibitors, for the prtevention of arterial thrombosis following
intravascular procedures. Patent Docket – 3-87907/USN, filed 1993.
D.S. Cohen and G.R. Marx. Use of novel nitric oxide donors for the treatment of angina,
pulmonary hypertension, and acute respiratory distress syndrome. Patent Docket – 3-64813/CGC
1586/Prov, filed 1992.
G.R. Marx and D.S. Cohen. Use of novel nitric oxide donors for the treatment of angina,
pulmonary hypertension, and acute respiratory distress syndrome. Can. Patent – 1,295,643.
IND Submissions (Section 6A) and NDA contributions:
QAD 163, Phosphodiesterase 5 inhibitor for erectile dysfunction
CGP 60536, Alliskirin, Renin antagonist
Amlopdipine/Valsartan, fixed combination of calcium channel blocker/ARB for hypertension

6. David S. Cohen Ph.D. Curriculum Vitae 6
CGS 30440, Vasopeptidase Inhibitor
CGP 48933, Valsartan, Angiotensin receptor antagonist
CGP 42112A, Angiotensin receptor antagonist (AT2)
CGS 24267A, Lotrel, Amlodipine plus Lotensin for hypertension
CGS 14824, Angiotensin Converting Enzyme Inhibitor
CGP 39393, recombinant Hirudin, Thrombin Inhibitor-antithrombotic
CGS 23305, Thromboxane Synthetase Inhibitor/Thromboxane Receptor Antagonist
CGS 22652, Thromboxane Synthetase Inhibitor/Thromboxane Receptor Antagonist
CGS 12970, Thromboxane Synthetase Inhibitor
CGS 13080, Thromboxane Synthetase Inhibitor
Invited Conference Participant :
• Presenter of Elutin Inc at AZ Bio Angel/Venture Capital Conference, Phoenix, AZ, 2015
• University of Nevada, Las Vegas Entrepreneurs Student Workshop, Las Vegas, NV 2013
• Drew University Symposium on Careers in Pharmaceutical Sciences, Madison, NJ, 2011
• Co-chaired American Society of Thrombosis satellite session, Las Vegas, NV, 2009
• Presented ‘Local Drug Delivery’ opportunities at IM4 Vancouver conference, 2007.
• Chaired ‘future antithrombotics’ workshop, MIT University, 2007.
• Presenter at IM3 Medical Device Company Forum on “synergies between Big Pharma and the
Medical Device Industry; opportunities for site-specific local drug delivery”, 2006.
• Co-Chairman of Antithrombotic Key Opinion Leader In-licensing Strategy Workshop, NewYork,
NY, 2005.
• Co-Chairman of Thrombosis Disease Strategy, Key Opinion Leader Advisory Board, Cambridge,
MA, 2004.
• Co-chairman of Drug-Eluting Stent, Key Opinion Leader Advisory Board, Cambridge, MA, 2004.
• Third International Symposium on Angiotensin Antagonism, London, UK, 2000.
• Second International Symposium on Angiotensin Antagonism, London, UK, 1999.
• Nitric Oxide in Health and Disease, Philadelphia, PA, 1993.
• Intercenter Cardiovascular/Atherosclerosis Research Conference, Ciba-Geigy, Lucerne,
Switzerland, 1993.
• Intercenter Cardiovascular/Atherosclerosis Research Conference, Ciba-Geigy, Horsham, UK,
1991.
• Intercenter Cardiovascular/Atherosclerosis Research Conference, Ciba-Geigy, Princeton, NJ,
1989.
• Intercenter Cardiovascular/Atherosclerosis Research Conference, Ciba-Geigy, Interlaken,
Switzerland, 1987.
• American Heart Association Satellite Symposium on Thromboxane Synthase Inhibition, Dallas,
TX, 1983.

7. David S. Cohen Ph.D. Curriculum Vitae 7
Society Memberships:
Nevada/Bio Governor’s office Working Group
Clarke County, NV Science and Technology Interdisciplinary Committee
European Society of Cardiology
The American Association for the Advancement of Science
The International Society of Thrombosis and Haemostasis
The American Council on Thrombosis
The New York Academy of Sciences
The American Heart Association
The American Society on Hypertension.
American Diabetes Association.
International Academy of Clinical and Applied Thrombosis/Hemostasis
American Society of Interventional Cardiology
Honorariums:
Fellow, International Society of Clinical and Applied Thrombosis
Fellow, American Society on Thrombosis
Fellow, The Society of Clinical and Applied Hypertension
Strathmore’s ‘Who’s Who’
Volunteer Experience:
Special Olympics of New Jersey, Baseball Coach
Association for the Help of Retarded Children, Bronx, NY and Livingston, NJ
Morris County, NJ Young Men’s Mentor Program
Fountain House, New York, NY
The Bowery Rescue Mission
Union County, NJ Food Bank
Three Square Food Bank, Las Vegas, NV
Youth Baseball Coach, Ramapo, NY and New Providence, NJ
Education:
Ph.D. University of Massachusettes School of Medicine, Worcester, MA
Thesis: Oxygen free radical-induced platelet and progenitor megakaryocyte membrane alterations:
effects on arterial thrombosis, flow mechanics and intra-arterial inflammation.
M.S. City University of New York, NY.
B.S. Biology, City College of New York, N.Y.

8. David S. Cohen Ph.D. Curriculum Vitae 8
Publications:
1. D.S. Cohen, J.E. Mathis, R.A. Dotson and Z. Stephan. The antiobesity and lipid altering actions of chronic
microsomal transport protein (MTP) inhibition in obese Zucker rats. Cardiovasac. Diabetology 2: 43-49,
2003.
2. Cohen, D.S. Dotson, R.A., Gagen, K.S., Webb, R.L., Trapani, A.J., Fink, C.A. Vasopeptidase Inhibition
improves renal function and reduces cardiac hypertrophy in rats with reduced renal mass. Cardiovasc. Res.
56: 15-21, 2002.
3. D. S. Cohen, J.E. Mathis, R.A. Dotson, S.R. Graybill and J.L. Robertson. Endothelin A/B receptor
antagonism improves renal function in chronic cyclosporine nephrotoxicity. Endothelin-Seventh Int Cong,
2001.
4. D.S. Cohen, J.E. Mathis, R.A. Dotson, S.R. Graybill and J.L. Robertson. The combination of angiotensin II
receptor antagonism with angiotensin converting enzyme inhibition in the rat remnant kidney model:
benefits over monotherapy. 4th
International Symposium on Angiotensin Antagonism, London, UK, 2001.
5. D.S. Cohen, C.A. Fink, A.J. Trapani, R.L. Webb, P.A. Zane and R.E. Chatelain. CGS 30440: a dual inhibitor
of angiotensin-converting enzyme and neutral endopeptidase 24.11. Cardiovasc. Drug Rev. 17: 16-39, 1999.
6. D.S. Cohen, J.E. Mathis, R.A. Dotson, S.C. Graybill and N.J. Wosu. The protective effects of CGS 30440, a
combined angiotensin converting enzyme (ACE) inhibitor and neutral endo-peptidase inhibitor, a model of
chronic renal failure: a comparison with ACE inhibition. J. Cardiovasc. Pharm.32: 87-95, 1998.
7. I. Vlattas, J. Dellureficio, D.S. Cohen, W. Lee, F. Clarke, R. Dotson, J. Mathis and H. Zoganas. Thia-
prostanoid analogs with combined thromboxane receptor antagonist-thromboxane synthase inhibitor
activities: synthesis and pharmacological evaluation. Bioorg. Med. Chem. Let. 4: 2067-2072, 1994.
8. I. Vlattas, J. Dellureficio, D.S. Cohen, W. Lee, F. Clarke, R. Dotson, J. Mathis and H. Zoganas. Oxa-
prostanoid analogs: identification of an orally effective dual thromboxane receptor antagonist-thromboxane
synthase inhibitor. Bioorg. Med. Chem. Let. 4: 2073-2076, 1994.
9. R.W. Olson, R. Dotson, J. Mathis, D.S. Cohen and R.L. Webb. Beneficial effects of combined thromboxane
synthase inhibition and receptor blockade in a canine model of coronary thrombosis. Eur. J. Pharmacol. 236:
75-87, 1993.
10. S.S. Bhagwat, C. Gude, D.S. Cohen, R. Dotson, J. Mathis, W. Lee and P. Furness. Thromboxane receptor
antagonism combined with thromboxane synthase inhibition 5. Synthesis and evaluation of enantiomers of 8-
4 chlorophenylsulfonylamino-4-3-pyridinylalkyloctanoic acid. J. Med. Chem. 36: 205-210, 1993.
11. A.J. Main, S.S. Bhagwat, C. Boswell, R. Goldstein, C. Gude, D.S. Cohen, P. Furness, W. Lee and M.
Louzan. Thromboxane receptor antagonism combined with thromboxane synthase inhibition.3.
Pyridinylalkyl-substituted 8-[(arysulfonyl)amino]octanoic acids. J. Med. Chem. 35: 4366-4372, 1992.
12. D.S. Cohen, D.N. McMartin, M.P. Marietta, P.A. Zane and R.W. Lappe. CGS 22652: a new potent
thromboxane A2 receptor antagonist with selective thromboxane A2 inhibitory properties. Cardiovasc. Drug
Rev. 10: 379-391, 1992.
13. S.S. Bhagwat, C. Boswell, C. Gude, N. Contardo, D.S. Cohen, J. Mathis, R. Dotson, W. Lee and
S. Shetty. Thromboxane receptor antagonism combined with thromboxane synthase inhibition 6. 4-substituted
3 pyridinylalkanoic acids. Bioorg. Med. Chem. Lett. 2: 1619-1622, 1992.

9. David S. Cohen Ph.D. Curriculum Vitae 9
14. S.S. Bhagwat, D.M. Roland, A.J. Main, C. Gude, K. Grim, R. Goldstein, D.S. Cohen, R. Dotson, J. Mathis
and W. Lee. Thromboxane receptor antagonism combined with thromboxane synthase inhibition 7.
Pyridinylalkyl-substituted arylsulfonylamino arylalkanoic acids. Bioorg. Med. Chem. Lett. 2: 1623-1626,
1992.
15. S.S. Bhagwat, C. Gude, C. Boswell, N. Contardo, D.S. Cohen, R. Dotson, J. Mathis, W. Lee, P. Furness and
H. Zoganas. Thromboxane Receptor antagonism combined with thromboxane synthase inhibition 4. 8-4
Chlorophenylsulfonyl-4-3-3-pyridinylpropyloctanoic acid and analogs. J. Med. Chem. 35: 4373-4383, 1992.
16. A.J. Main, S.S. Bhagwat, C. Boswell, R. Goldstein, C. Gude, D.S. Cohen, P. Furness, W. Lee and M.
Louzan. Thromboxane Receptor antagonism combined with thromboxane synthase inhibition 3.
Pyridinylalkyl-substituted 8 arylsulfonylaminooctanoic acids. J. Med. Chem. 35: 4366-4372, 1992.
17. A.J. Main, R. Goldstein, D.S. Cohen, P. Furness and W. Lee. Thromboxane Receptor antagonism combined
with thromboxane synthase inhibition 2. Synthesis and biological activity of 8-benzenesulfonamido-7-
3pyridinyloctanoic acid and related compounds. J. Med. Chem. 35: 4362-4365, 1992.
18. S.S. Bhagwat, C. Gude, D.S. Cohen, W. Lee, P. Furness and F.H. Clarke. Thromboxane Receptor
antagonism combined with thromboxane synthase inhibition.1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic
acids. J. Med. Chem. 34: 1790-1797, 1991.
19. D.S. Cohen, E.C. Ku, E.F. Kimble, H.B. Renfroe and E.F. Smith. CGS 15435A, a thromboxane synthetase
inhibitor with an extended duration of action - a comparison with dazoxiben. Eur. J. Pharmacol. 133: 265-
273, 1987.
20. D.S. Cohen, D.I. Cargill, R.G. VanValen, J.J. Klimek and R.P. Levin. Aggregation, release and
desensitization induced in platelets from 5 species by platelet activating factor (PAF). Thromb. Haeomostas.
49: 204-207, 1983.
21. H.J. Weiss, H.R. Baumgartner, T.B. Tschopp, V.T. Turitto and D.S. Cohen. Correction by factor VIII of the
impaired platelet adhesion to subendothelium in von Willebrand disease. Blood 38: 297-301, 1978.
Abstracts:
1. D.S. Cohen, J.E. Mathis, R.A. Dotson, S. Graybill and J.L. Robertson. The combination of valsartan, an AII
antagonist, with benazepril, an ACE inhibitor, in rats with reduced renal mass: benefits over monotherapy.
2nd
Intl Symp on AII Antagonism, Feb, 1998.
2. D.S. Cohen, J.E. Mathis, R.A. Dotson, S. Graybill and J.L. Robertson. The lack of efficacy of endothelin
(ET) antagonism in rats with reduced renal mass. FASEB J. 12:663, 1998.
3. D.S. Cohen, J.E. Mathis, R. Dotson, S. Graybill and J.L. Robertson. The effects of valsartan (Va), an
angiotensin II receptor antagonist, plus benazepril (B), an ACEI on renal function in the rat remnant kidney
model. JASN 7: 6, 1996.
4. D.S. Cohen, J.E. Mathis, R.A. Dotson, S.C. Graybill and N.J. Wosu, Improved efficacy of a combination of
angiotensin converting enzyme inhibition (ACEI) and neutral endopeptidase inhibition (NEPI) over ACEI
alone in a model of chronic renal failure. JASN 6: 1011, 1995.
5. D.S. Cohen, J.E. Mathis and R.A. Dotson. GEA 3175, a novel new nitric oxide (NO) donor: a comparison
with sodium nitroprusside. FASEB J. 9: A923, 1995.

10. David S. Cohen Ph.D. Curriculum Vitae 10
6. R.A. Dotson, J.E. Mathis, H.H. Hsu and D.S. Cohen. Benazepril (BZ), an angiotensin converting enzyme
inhibitor, improves kidney function in a model of chronic renal failure in spontaneously hypertensive rats
(SHR). FASEB J. 9: A685, 1995.
7. S.C. Graybill, R.A. Dotson, J.E. Mathis, H.H. Hsu and D.S. Cohen. The dose-dependent effects of
benazepril, an angiotensin converting enzyme inhibitor, on the improvement of renal function in chronic
renal failure in 5/6 renal ablated normotensive Sprague-Dawley rats. FASEB J. 9: A685, 1995.
8. J.E. Mathis, R.A. Dotson, S.C. Graybill, H.H. Hsu and D.S. Cohen. Preservation of renal function in a model
of chronic renal failure: the effects of angiotensin converting enzyme inhibition (ACEI) vs. neutral
endopeptidase inhibition (NEPI). FASEB J. 9: A686, 1995.
9. J. Rediske, D. Cohen, J. Mathis, R.L. Goldberg, S. Spirito, R. Ghai, C. Berry and C. Koehne. The inducible
nitric oxide (NO) synthesis pathway in articular chondrocytes. Arthritis and Rheumatism 36: R36, 1993.
10. R.A. Dotson, J.E. Mathis and D.S. Cohen. Characterization of two nitric oxide (NO) releasing agents in
arterial and venous tissue. FASEB J. 7: A259, 1993.
11. J.E. Mathis, R.A. Dotson and D.S. Cohen. Sodium nitroprusside (SNP), SIN-1 and glyceryl trinitrate (GTN):
an in vitro comparison of their nitric oxide releasing characteristics and their antiplatelet activity. FASEB J.
7: A261, 1993.
12. D.S. Cohen, R.A. Dotson, J.E. Mathis, H.C. Zoganas, J.P. Simke, R.W. Olson, S.S. Bhagwat and R.L. Webb.
CGS 23305: in vivo and ex vivo characterization of a thromboxane (Tx) A2 receptor antagonist/Tx synthase
inhibitor (TxSI). FASEB J. 6: A999, 1992.
13. R. Dotson, D. Cohen, J. Mathis, P. Furness, W. Lee, S. Bhagwat and C. Gude. CGS 23305: in vitro
characterization of a potent thromboxane A2/prostaglandin H2 (TxA2/PGH2) receptor antagonist and
thromboxane synthase inhibitor. FASEB J. 6: A1599, 1992.
14. D.S. Cohen, S. Bhagwat, R. Dotson, J. Mathis, P. Furness, M. Louzan, W. Lee, J. Peppard and C. Gude. In
vitro characterization of CGS 22652, a combined thromboxane receptor antagonist (TXRA)/thromboxane
synthase inhibitor (TXSI). Thromb. Haemostas. 65: 1372, 1991.
15. D.S. Cohen, R. Dotson, J. Mathis, H. Zoganas, W.M. Coram, M. Louzan and S. Bhagwat. The effects of
CGS 22652, a potent dual thromboxane receptor antagonist (TXRA)/thromboxane synthase inhibitor (TXSI),
in vivo. Thromb. Haemostas. 65: 1734, 1991.
16. R.L. Webb, R.W. Olson, R. Dotson, J. Mathis and D.S. Cohen. Beneficial effects of CGS 22652, a
thromboxane receptor antagonist/thromboxane synthase inhibitor as an adjunct to streptokinase (SK) therapy
in a canine model of coronary thrombosis. Thromb. Haeomostas. 65: 1177, 1991.
17. S.S. Bhagwat, A.J. Main, C. Gude, C. Boswell, N. Contardo, R. Goldstein, D.S. Cohen, R. Dotson, M.
Louzan, J. Mathis, W. Lee, P. Furness, L. Autry, W. Coram and H. Zoganas. Thromboxane receptor
antagonism combined with thromboxane synthase inhibition. Synthesis and evaluation of CGS 22652 and its
analogs. Gordon Conference, 1991.
18. R. W. Olson, D.S. Cohen and R.L. Webb. Efficacy of thromboxane (TX) modulators as adjuncts to
streptokinase (SK) therapy. Arteriosclerosis 10: A942, 1990.
19. D.S. Cohen, E.F. Kimble, E.F. Smith III, R.W. Olson, G.G. Bastastini, E.C. Ku and H.B. Renfroe. CGS
14854, a potent selective long-acting thromboxane synthetase inhibitor is effective in rabbits, dogs and
monkeys. Fed. Proc. 45: 924, 1986.

11. David S. Cohen Ph.D. Curriculum Vitae 11
20. D.S. Cohen, T.D. Oglesby and E.C. Ku. Synergistic inhibition of platelet function in vivo by a thromboxane
synthetase inhibitor and modulator of cAMP. Thromb. Haemostas. 54: 133, 1985.
21. D.S. Cohen, H.J. Povalski, R.K. Rinehart, C. Tsai, B.W. Barclay, D. VanOrsdell and Y. Sakane. Inhibition
of thromboxane A2 (TXA2) synthetase causes endoperoxide shunting towards PGI2 and PGE2 synthesis in
canine whole blood. Fed. Proc. 42: 640, 1983.
22. D.S. Cohen, H.J. Povalski, R.K. Rinehart, C. Tsai, B.W. Barclay, D. VanOrsdell and Y. Sakane.
Thromboxane A2 (TXA2) synthetase inhibition results in endoperoxide shunting towards PGI2 and PGE2
synthesis in canine whole blood. Thromb. Haemostas. 50: 285, 1983.
23. D.S. Cohen, J.M. Strohschein, R.N. Saunders and D.I. Cargill. Platelet factor 4 release from unstimulated
human platelets. Thromb. Haemostas. 46: 132, 1981.
24. D.S. Cohen, D.I. Cargill, R. VanValen, M.L. Lee and R.N. Saunders. Platelet activating factor (PAF) -
induced aggregation and release responses in vitro in 3 species. Thromb. Haemostas. 46: 292, 1981.
25. V.T. Turitto, H.J. Weiss and D.S. Cohen. Interaction of human platelets with subendothelium: implications
for measurement of defects in platelet function. Thromb. Haemostas. 38: 297, 1977.